BioSmart Rises 29.83% Amid COVID-19 (Diagnostic Kit) Theme Uptrend

On the 27th, the COVID-19 (diagnostic kit) theme rose 3.14% compared to the previous day, showing strength, while Biosmart, a related stock drawing attention, surged 29.83% compared to the previous day. Biosmart is known as a credit card manufacturer and cosmetics manufacturing and distribution company.

[Graph] Major stock price changes in the COVID-19 (diagnostic kit) theme

According to provisional data compiled at 10:51, foreign investors have sold -85,800 shares of Biosmart, indicating a large net selling by foreigners.

[Table] Net trading volume of foreigners and institutions (unit: 10,000 shares)

According to the analysis by Thinkpool RoboAlgorithm RASSI, Biosmart exceeded the average scores of the theme in growth, stability, and profitability, ranking 3rd in the quant financial ranking (out of 33 stocks). This can be interpreted as Biosmart having relatively high investment attractiveness compared to other stocks within the theme from a financial perspective.

[Table] Top stocks by financial score within the theme

※ The quant financial score is the result of RoboAlgorithm's analysis based on each company's sales growth rate, equity growth rate, debt ratio, current ratio, ROA, ROE, etc.

※ This article was generated in real-time by an article automatic generation algorithm jointly developed by Asia Economy and the financial AI specialist company Thinkpool.

This content was produced with the assistance of AI translation services.